Takeda Pharmaceutical Company Limited Share Price
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,425.00 JPY | +2.96% |
|
-7.22% | +12.20% |
| 02:53am | Takeda Wins FDA Approval for First-in-Class Narcolepsy Treatment ORZEYFUL | MT |
| 12:05am | Takeda Receives U.S. Fda Approval for Orzeyful (Oveporexton) to Treat Narcolepsy Type 1 | CI |
| Market Cap | 8,662B 54.98B 47.61B 44.38B 40.82B 77.07B 5,227B 77.93B 522B 205B 2,616B 206B 202B | P/E 2027 * |
43.6x | P/E 2028 * | 27x |
|---|---|---|---|---|---|
| Enterprise Value | 12,589B 79.89B 69.2B 64.5B 59.33B 112B 7,597B 113B 758B 297B 3,801B 300B 293B | EV / Sales 2027 * |
2.7x | EV / Sales 2028 * | 2.62x |
| Free-Float |
99.28% | Yield 2027 * |
3.77% | Yield 2028 * | 3.84% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +2.96% | ||
| 1 week | -7.22% | ||
| Current month | -1.60% | ||
| 1 month | +1.23% | ||
| 3 months | +3.55% | ||
| 6 months | -2.99% | ||
| Current year | +12.20% |
| 1 week | 5,225 |  | 5,578 |
| 1 month | 5,225 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 23/06/2026 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 31/03/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 31/05/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 31/12/2018 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 31/05/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 10/07/26 | Issuer sale | President, Japan Pharma B.U. | -1,022 | 0.0001% | ||
| 10/07/26 | Issuer sale | Director | -1,152 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.96% | -7.22% | +28.74% | +24.88% | 53.39B | |
| +0.72% | +2.34% | +58.37% | +160.31% | 1,043B | |
| -0.50% | +0.22% | +50.29% | +48.11% | 621B | |
| -0.97% | -5.35% | +24.12% | +62.08% | 435B | |
| 0.00% | +3.20% | +46.70% | +37.70% | 361B | |
| +0.58% | -1.26% | +35.52% | +39.32% | 293B | |
| -1.55% | -6.84% | +7.20% | +8.86% | 251B | |
| -1.18% | +4.01% | +41.63% | +59.39% | 220B | |
| -0.24% | -11.27% | +1.42% | -46.20% | 201B | |
| -1.37% | -0.88% | +18.00% | +61.31% | 164B | |
| Average | -0.10% | -4.42% | +31.20% | +45.58% | 364.25B | |
| Weighted average by Cap. | -0.11% | -3.88% | +39.97% | +73.19% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,668B 29.63B 25.66B 23.92B 22B 41.53B 2,817B 42B 281B 110B 1,410B 111B 109B | 4,747B 30.13B 26.09B 24.32B 22.37B 42.23B 2,865B 42.7B 286B 112B 1,433B 113B 111B |
| Net income | 191B 1.21B 1.05B 977M 898M 1.7B 115B 1.71B 11.48B 4.5B 57.56B 4.54B 4.44B | 316B 2.01B 1.74B 1.62B 1.49B 2.81B 191B 2.85B 19.05B 7.47B 95.51B 7.54B 7.37B |
| Net Debt | 3,926B 24.92B 21.58B 20.12B 18.5B 34.93B 2,369B 35.32B 236B 92.79B 1,186B 93.59B 91.52B | 3,764B 23.89B 20.69B 19.29B 17.74B 33.49B 2,272B 33.86B 227B 88.96B 1,137B 89.73B 87.75B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/08/26 | JP¥5,425.00 | +2.96% | 4,077,000 |
| 05/08/26 | JP¥5,269.00 | -0.32% | 3,470,800 |
| 04/08/26 | JP¥5,286.00 | -2.26% | 3,851,800 |
| 03/08/26 | JP¥5,408.00 | -1.90% | 4,750,600 |
| 31/07/26 | JP¥5,513.00 | -3.59% | 7,218,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
